昂利康：股票交易异常波动

Core Viewpoint - The stock price of Anglikon has experienced a significant deviation, with a cumulative increase of over 20% over two consecutive trading days, triggering an abnormal trading fluctuation notice [1] Company Information - Anglikon confirmed that there is no need to correct or supplement previously disclosed information, and there are no major undisclosed matters regarding the company's operations [1] - The company is currently conducting a Phase I clinical trial for its innovative drug project ALK-N001, which involves long research cycles, substantial investment, and uncertain outcomes [1]